Our studies suggest that evaluation of combined LSD1 and mTORC1 inhibition in MLL-translocated AML, perhaps following intensive chemotherapy and remission induction, with the goal of inducing differentiation of minimal residual disease may prove beneficial. The gene discussed is KDM1A; the disease is acute myeloid leukemia.